Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial of AAB-001 in Mild to Moderate Alzheimer's Disease
2004-004120-12Phase 2Completed
- Sponsor
- Elan
- Start
- Feb 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing AAB-001 multiple ascending dose with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events and Safety and tolerability. Started Feb 2005; status: completed.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2004-004120-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004120-12.